S. 3267 · 119th Congress · Health

ASAP Act

In committee280 words Introduced Nov 20, 2025 · Latest action Nov 20, 2025

How far it has goneStage 2 of 6
  1. IntroducedNov 20, 2025 Done
  2. CommitteeReferred to Finance Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill provides for Medicare coverage of blood tests to screen for the early stages of Alzheimer’s disease or related dementias. Specifically, the bill provides for coverage of genomic sequencing blood or blood product tests, or other equivalent tests, that are approved by the Food and Drug Administration.

Congressional Research Service · summary of “Introduced in Senate” version · Nov 20, 2025

Who lobbies on it

5 organizations, more than 92% of Senate bills · 14 filings · Q4 2025–Q3 2026

These 5 organizations’ PACs gave $137K to 23 of the 60 members sponsoring or cosponsoring S. 3267 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the Senate → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Alzheimer's Association 4 of 4 quarters
    “General issues related to detection, diagnosis and treatment of Alzheimer's and all other dementia; including the Alzheimer's Screening and Prevention Act of 2025 (H.R. 6130/S. 3267)”

    $3.7M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  2. Biogen 3 of 4 quarters
    “…S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review…”

    $3.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing

  3. Eisai Inc. 2 of 4 quarters
    “General issues related to Medicare and Medicaid, including: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order; Part D Program; enter for Medicare and Medicaid Innovation (CMMI) Drug Pricing Demonstration Programs; drug pricing, PBM reform; H.R. 6130 / S. 3267, the Alzheimers…”

    $1.7M lobbying spend in 2026 to date, all issuesQ3 2026 filing

2 more organizations, every filingPROUpgrade

Organizations that named S. 3267 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Nov 20, 2025Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279)
  2. Nov 20, 2025Introduced in Senate

What members said about it